Introduction

Mitochondrial disease shows various clinical manifestations such as neuromuscular disorders, including muscle weakness, encephalopathy, mental disorder and neurosensory deafness, cardiomyopathy, short stature and diabetes mellitus. Of these disorders, diabetes mellitus is known as maternal inherited mitochondrial diabetes mellitus (MDM), which is identified in up to 1% of all patients with diabetes mellitus. The mitochondrial DNA 3243 A>G mutation is the most common genetic abnormality (80-90%), whereas other mutations, such as 8296 A>G and 14577 T>G, are less frequent [1]. Diabetes mellitus is the most common endocrine disorder in mitochondrial disease, because mitochondrial dysfunction greatly affects pancreatic β-cells, leading to insulin secretion defect [2]. Coenzyme Q10 (CQ10) is well known to act as an electron carrier of the respiratory chain in mitochondria and has been shown to improve the mutation-associated dysfunction of the respiratory chain in mitochondria. Various reports demonstrated that administration of CQ10 had some clinical benefits toward neuromuscular symptoms [3], elevated lactate levels [4], and neurosensory deafness [5]. On the other hand, there were few reports showing improvement in glycemic control and endogenous insulin secretion when using CQ10 in patients with MDM [5,6]. We encountered a case of MDM with the mitochondrial DNA 3243 A>G mutation, and hereby reported changes in glycemic control and other clinical manifestations after administration of CQ10.

Case Report

A 25-year-old woman presented to our hospital with leg numbness, malaise, headache and muscle weakness, which had existed for 1-month period. She was already diagnosed with Wolff-Parkinson-White syndrome at 12 years old. She was later diagnosed as diabetes mellitus without autoimmune disorders at 15 years old, and the mitochondrial DNA 3243 mutation was detected by the gene analysis. Neurosensory deafness was identified at 16 years of age, and hypertrophic left ventricular cardiomyopathy was detected at 24 years of age. We started administration of coenzyme Q10 (CQ10), and subsequently her clinical symptoms and glycemic control were improved accompanied by decreasing blood lactate level. We assessed neurological signs of MDM using the Japanese Mitochondrial Disease Rating Scale (JMDRS). The JMDRS was improved from 12/80 points at the start of CQ10 to 5/80 points at 12-month period after starting CQ10. These findings suggest that CQ10 treatment could be effective on clinical symptoms, a lactate level and glycemic control in a patient with MDM.
glucosuria through a urine glucose screening at schools at 15 years of age and identified as having diabetes in the detailed examination of the screening program. She was not obese with body mass index (BMI) of 18.8kg/m², β-cell associated antibodies were all negative, and insulin secretion capacity was maintained at the time of diagnosis. There were no neuromuscular symptoms, including muscle weakness, fatigue and impaired hearing, at that time. Subsequently, maturity-onset diabetes of the young (MODY) genes and mitochondrial DNA genes were analyzed, and the mitochondrial DNA 3243A>G mutation was detected (Figure 1).

Neurosensory deafness was identified by an audiogram at 16 years of age, and hypertrophic left ventricular cardiomyopathy was detected at 24 years of age. Her 53-year-old mother and 24-year-old younger sister were also identified as the mitochondrial DNA 3243A>G mutation at the same time as this patient. Her mother already had diabetes mellitus, neurosensory deafness and Hashimoto disease. Her sister had no clinical symptom associated with the mitochondrial DNA mutation. Upon hospitalization, the patient’s height, body weight, and BMI were 155.4cm (-1.6 SD), 44.5kg and 18.4kg/m², respectively. There was neither muscle weakness nor muscle atrophy in the upper and lower extremities, and her sense of touch and pressure at the extremities was normal. The Achilles tendon reflex and peripheral sensation were diminished; bilateral pure tone was 40-50dB. Fasting plasma glucose (FPG) level was 181 mg/dL, HbA1c level 10.3%, Plasma C-peptide immunoreactivity (CPR) level 0.25ng/dL, and blood lactate level 28.8mg/dL. Electrocardiogram showed WPW syndrome. Computed tomography images showed no calcification, but mild atrophy of the whole brain and cerebellum was detected by magnetic resonance imaging. These findings suggested aggravation of glycemic control and decreasing insulin secretion possibly due to progression of mitochondrial dysfunction. We tried to use CQ10 of 30 mg concomitant with prosultiamine of 225mg, levocarnitine chloride of 300mg, and tocopherol acetate of 100mg daily aimed to rescue the mitochondrial dysfunction proposed by previous studies [3-6].

To evaluate clinical effect of CQ10 treatment on glycemic control and endogenous insulin secretion, we examined HbA1c and plasma CPR levels after administration of CQ 10. We conducted glucagon loading test (CPR levels at 3, 6, 9, and 15 minutes after administration of glucagon of 1mg) to evaluate furthermore endogenous insulin secretion. We also examined blood lactate levels and assessed neurological signs of MDM using the Japanese Mitochondrial Disease Rating Scale (JMDS). The JMDS was revised following the European Neuromuscular Center mitochondrial disease rating scale in 2003 [7-9]. The JMDS is useful for evaluation of clinical symptoms of MDM and has enabled longitudinal analysis of disease progression. Figure 2 shows the clinical course after administration of CQ10. Self-monitored FPG and HbA1c levels were improved from 181mg/dL, 10.3% before using CQ10, 157mg/dL, 8.5% at 2-month period, 130mg/dL, 7.2% at 7-month period and 105mg/dL, 6.8% at 12-month period after using CQ10. Fasting CPR levels before and 2 months, 7 months and 12 months after using CQ10 were 0.21, 0.53, 0.68 and 0.70ng/mL, respectively. There was also improvement in plasma CPR reaction on glucagon loading test as shown in Figure 3. On the other hand, there was no increase in the daily insulin dose. Blood lactate levels decreased from 28.8mg/dL before using CQ10 to below 10 mg/dL during using CQ10. The JMDS was 12/80 points at the start of CQ10, and decreased to 10/80 points at 2-month period, 9/80 points at 7-month period and 5/80 points at 12-month period after starting CQ10. There was no need to increase the insulin dose. There were no problematic adverse events during use of CQ10.
Cite this article: Masako Aoki, Junichi Suzuki, Tatsuhiko Urakami. Effect of Coenzyme Q10 Treatment on Clinical Manifestations in a Young Woman with Mitochondrial Diabetes. Biomed J Sci&Tech Res 11(1)-2018. BJSTR. MS.ID.002030. DOI: 10.26717/BJSTR.2018.11.002030.

Discussion

CQ10 is an essential electron carrier in the mitochondrial respiratory chain. It acts as an electron carrier in the electron transport chain from complex I-Ⅱ to complex Ⅱ-Ⅲ, and is present in all tissues and cells in the inner mitochondrial membrane [10]. CQ10 is also a lipid-soluble antioxidant and scavenges reactive oxygen species [11]. The mechanisms connecting mitochondrial DNA 3243 mutations and onset of diabetes are thought to be as follows:

a) Accelerated production of reactive oxygen species and increased oxidative stress,

b) Reduced oxidative phosphorylation and decreased ATP levels in pancreatic β-cells,

c) Damaged signal transduction in pancreatic β-cells and reduction in their cell numbers due to apoptosis,

d) Exhaustion of insulin secretion [12-14].

CQ10 plays a role in stopping step 1), thereby preventing progression to steps 2), 3), and 4). Accordingly, administration of CQ10 might prevent the advance to insulin exhaustion; improving insulin secretion and glycemic control. Richter et al. [15] reported that insulin secretory defects may result from anti-oxidation activities and dysfunction in the mitochondrial respiratory chain. Administration of CQ10 can stop the dysfunction of the mitochondrial respiratory chain and insulin secretion could be improved. The course of the patient described showed important clinical information of possibility of improvement in glycemic
control and endogenous insulin secretion as well as clinical symptoms and a blood lactate level with using CQ10 in MDM. There are some reports showing therapeutic effects on neuromuscular symptoms and a blood lactate level [3-6].

On the other hand, there were few reports showing improvement in glycemic control and endogenous insulin secretion when using CQ10 in patients with MDM [5,6]. Okazaki et al. [6] reported a large dose of CQ10 (60 mg/day) was effective to improve HbA1c levels from 8.5% to 7.5% and to increase glucagon loading CPR levels from 1.8 ng/dL to 2.0 ng/mL at the study of 2-year period. There were some other case reports demonstrating the efficacy of CQ10 on glycemic control for a short period less than 1 year [5,16,17]. Reported more increase in CRR response on glucagon loading test and urinary excretion of CPR among 28 patients with MDM compared with 16 patients without receiving CQ10 treatment for 3-year study period. As compared to the studies conducted by Okazaki et al. [5,6] our study period for 1 year is shorter, and it seems too early to judge the effect of CQ10 on glycemic control and endogenous insulin secretion. Longer-term follow-up should be necessary to evaluate the effect of CQ10 on diabetic control in our case. On the other hand, we started some medication, such as prosultiamine, levocarnitine chloride and tocopherol acetate, other than administration of CQ10. These drugs could play a role to improve mitochondrial function with increasing endogenous insulin secretion and reducing plasma glucose levels. In conclusion, we reported the clinical course with CQ10 treatment in the case of MDM presenting with mitochondrial DNA 3243A>G mutation. CQ10 treatment could be effective on clinical symptoms, a lactate level and glycemic control in a patient with MDM.

Disclosure

We obtained consent to write this report from the patient, her younger sister, and mother. None of the authors have any potential conflicts of interests to this case report.

References

1. Okazaki Whittaker R, Skaefer A, McFarland R (2007) Prevalence and progression of diabetes in mitochondrial disease. Diabetesologia 50(10): 2085-2089.
2. Schaefer AM, Walker M, Turnbull DM, Taylor RW (2013) Endocrine disorders in mitochondrial disease. Mol Cell Endocrinol1379(1-2): 2-11.
3. Suzuki Y, Tanigaya M, Muramatsu M, Atsumi Y, Hosokawa K, et al. (1997) Diabetes mellitus associated with 3243 mitochondrial tRNA (Leu (UUR)) mutation; clinical features and coenzyme Q10 treatment. Mol Aspects Med 18 Suppl: 181-188.
4. Suzuki Y, Kadowaki H, Atsumi Y, Hosokawa K, Katagiri H, et al. (1995) A case of diabetic amyotrophy associated with 3243 mitochondrial tRNA (Leu; UUR) mutation and successful therapy with coenzyme Q10. Endocr J 42(2): 141-145.
5. Suzuki S, Hinoki Y, Ohtomo M (1998) The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. Diabetesologia 41: 584-588.
6. Okazawa M, Iwata M, Takigawa S (2009) High dose administration of CQ10 improved hearing loss in a case of mitochondrial diabetes mellitus. Journal of Diabetes Society 5: 463-467.
7. Chinnery PF, Bindoff LA (2003) 116th ENMC international workshop: the treatment of mitochondrial disorders, 14th-16th March 2003, Naarden, The Netherlands. Neuromuscul Disord 13: 757-764.
8. Phoenix C, Schaefer AM, Elson JL (2006) A scan of monitor progression and treatment of mitochondrial disease in children. Neuromuscul Disord 16(12): 814-820.
9. Joao E, Valdir A, Dirceu R, Antonio R, Regina S (2006) Myocardial dysfunction in mitochondrial diabetes treated with Coenzyme Q10. Diabetes Res Clin Pract 72(1): 100-103.
10. Catarina M, Quinzii, Hirano M (2010) Coenzyme Q10 and mitochondrial disease. Dev Disabil Res Rev 16: 103-108.
11. Turunen M, Olsson J, Dalner G (2004) Metabolism and function of coenzyme Q. Biochem Biophys Acta 1660(1): 171-199.
12. Chu CS, Chu CL, Liu HR, Lu T (2012) Regain of visuospatial capacity after coenzyme Q10 in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes: a case report. Acta Neuropsychiatr 24(3): 186-188.
13. Kura A, Goldstein A (2014) The spectrum of clinical presentation, diagnosis, and management of mitochondrial forms of diabetes. Pediatr Diabetes 16(1): 1-9.
14. Nishikawa T, Yamashiro T, Kakidome T, Araki E (2009) Mitochondria; mitochondrial diabetes and treatment. Diabetes Frontier 20: 343-348. (in Japanese).
15. Richer C (1995) Oxidative damage to mitochondrial DNA and its relationship to aging. Int J Biochem Cell Biol 27(7): 657-653.
16. Usui I, Sawa T, Inoue A (1995) A case of diabetes mellitus with a mitochondrial DNA 3243 mutation treated with large dose of Coenzyme Q. Journae of the Japanese Society of Internal Medicine 94: 1904-1906.
17. Izumi T, Watanabe G, Omoto K, Nakamura S (1997) Clinical effect of Coenzyme Q10 on chronic progressive external ophthalmoplegia associated with impaired glucose tolerance and macrocytic anemia. Neurological Therapeutics 14: 569-573.

ISSN: 2574-1241
DOI: 10.26717/BJSTR.2018.11.002030

Tatsuhiko Urakami. Biomed J Sci & Tech Res

This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: https://biomedres.us/submit-manuscript.php

Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

Cite this article: Masako Aoki, Junichi Suzuki, Tatsuhiko Urakami. Effect of Coenzyme Q10 Treatment on Clinical Manifestations in a Young Woman with Mitochondrial Diabetes. Biomed J SciTech Res 11(1)-2018. BJSTR. MS.ID.002030. DOI: 10.26717/BJSTR.2018.11.002030.